MONTREAL, Nov. 16 /PRNewswire-FirstCall/ - Procyon Biopharma Inc. , a biotechnology company developing innovative therapeutics in the fields of cancer and HIV/AIDS, announced today that it will be hosting a conference call and webcast to explain the implications of PPL-100 resistance selection study's important scientific findings on Wednesday, November 16th at 4:00 PM ET.
Hans J. Mader, president and chief executive officer of Procyon Biopharma, Dr. Chandra Panchal, senior vice-president of new technologies of Procyon Biopharma as well as Dr. Jinzi Wu, vice-president, preclinical and basic research of Procyon Biopharma, will be on the call to explain the new data and answer questions.
Interested parties may access the conference call by way of telephone or webcast. The webcast will be available at www.procyonbiopharma.com and archived for 90 days for replay purposes. The numbers to access the conference call are (416) 644-3414 (U.S. and Canada) and 1(800) 814-4853 (international). A replay of the call will be available from November 16th to February 16th and the numbers to access the replay are (416) 640-1917 (U.S. and Canada) and 1(877) 289-8525 (international) with access code 21164107(pound key).
PPL-100, is a phosphorylated Pro-drug of Procyon's PL-100 protease inhibitor. PL-100 is the active antiviral agent that is potent, specific and non-cytotoxic with a favorable cross-resistance profile in drug and multi-drug resistant strains of HIV-1. PL-100 is active against several HIV-1 strains specifically selected for key mutations that render these strains resistant to currently-marketed protease inhibitors. Preclinical safety studies as well as animal pharmacokinetic studies have recently been completed and human clinical studies expected to commence by the end of the year.
ABOUT PROCYON BIOPHARMA INC.
Procyon Biopharma Inc. is a biotechnology company actively engaged in the discovery and development of innovative therapeutics in the fields of cancer and HIV/AIDS. The Company leverages its strengths in research and clinical development, bringing products through late-stage clinical trials and then evaluating the best options for further development, such as co-development and licensing. Procyon's pipeline includes: PCK3145, a non-toxic peptide soon to enter a Phase II North American trial for the treatment of advanced metastatic prostate cancer; TVT-Dox, a tumor vasculature targeting technology for the treatment of solid tumors for which an IND filing is expected within 12 months; and, PPL-100, a protease inhibitor for the treatment of drug- resistant HIV/AIDS soon to enter the clinic. Procyon has won the 2005 Frost & Sullivan Award for Excellence in Technology for its overall scientific and technological contributions towards the advancement of cancer therapy. Headquartered in Montreal, Procyon shares are listed on the Toronto Stock Exchange (TSX) under the ticker symbol PBP. For more information, visit www.procyonbiopharma.com.
This release contains forward-looking statements that reflect the company's current expectation regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company's filings.
PROCYON BIOPHARMA INC.
CONTACT: Procyon Biopharma Inc.: Julie M. Thibodeau, Director,Communications, (514) 685 2000 ext 118, email@example.com,firstname.lastname@example.org